Merge of DRGs 301B and 910C
|Target version:||Expert Group 2016|
|Case type:||Owner / responsible:||National organisations|
|MDC:||MDC10||Old forum status:|
There have been no cases in DRG 910C (Malignancy of endocrine, nutritional and metabolic system, demanding isotope therapy, short therapy; Endokrin malignitet, krävande isotopbehandling, kort vård) in 2013 in five Finnish University hospital. Unlikely there will be any (or if there will be any then very few) mainly due to the clinical characteristics of the patients in need demanding isotope therapy.
We suggest merging the DRGs 910C and 301B (Endocrine cancer disease, demanding isotope therapy; Endokrin malignitet, krävande isotopbehandling) so that the length of stay has no effect on grouping.
There have been 8 cases in DRG 301B in 2013, mean cost 2 090 EUR, stdev 813 EUR and V% 39%.
#2 Updated by Mats Fernström over 4 years ago
Mats Fernström, NPK, Sweden 2016-02-04
As far as we can see, we don’t have any Swedish DRGs corresponding to 301B and 910C. But if there are, we don’t want to merge them. As a basic principle we don’t want to have the same DRG codes (on four digit level) for inpatients and outpatients.
#3 Updated by Kristiina Kahur over 4 years ago
Finnish National DRG-Centre 2016-2-25
Thank you for your comments and feedback.
We agree on and respect the principle of not merging the outpatient and inpatient DRGs. Therefore we suggest to remove the rule of DRG 910C (110D102030) instead of merging it with one of DRG 301B.
As there have been no cases in DRG 910C so far, this change should not cause any changes in DRG grouping. Nevertheless, in unlikely event the cases which may group to DRG 910C will be grouped to other outpatient DRGs according to diagnosis and procedure codes of given cases.
#4 Updated by Kristin Dahlen over 4 years ago
Norwegian Directorate of Health - 09.03.2016
We don't have any DRG corresponding to 910C and 301B. We do have a DRG 910C in the Norwegian version, but this DRG have a different meaning. In Norway we have split DRG 910 into the following Groups:
910A Poliklinisk konsultasjon vedrørende diabetes mellitus
910B Poliklinisk konsultasjon vedrørende sykdom i skjoldbruskkjertelen
910C Poliklinisk konsultasjon vedrørende fedme og overvekt
910O Poliklinisk konsultasjon vedr andre endokrine/ ernærings-/ stoffskiftesykdommer
#6 Updated by Kristiina Kahur over 4 years ago
Finnish National DRG-Centre 2016-3-11
To combine 910C with 910B would be an option indeed. In that case the name of 910B should be corrected since it would involve not olny the case with stereotactic radiotherapy but also the ones with demanding isotope therapy. Thus, it could be e.g. “Malignancy of endocrine, nutritional and metabolic system, stereotactic radiotherapy or demanding isotope therapy, short therapy”. Very long name.